Showing results (31-40 of 61) with videos related to

Sort By:
Pageof 7
International Journal of Clinical Practice|May 17, 2017
Treatment patterns and outcomes of Stage IIIB/IIIC melanoma in France, Germany and the UK: A retrospective and prospective observational study (MELABIS)Mark Harries, Peter Mohr, Florent Grange, et al.
Melanoma Research|August 12, 2017
Economic burden of advanced melanoma in France, Germany and the UK: a retrospective observational study (Melanoma Burden-of-Illness Study)Florent Grange, Peter Mohr, Mark Harries, et al.
British Journal of Haematology|March 22, 2003
Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphomaIan Chau, Mark Harries, David Cunningham, et al.
Molecular Cancer Therapeutics|November 12, 2014
Effects of BRAF mutations and BRAF inhibition on immune responses to melanomaKristina M Ilieva, Isabel Correa, Debra H Josephs, et al.
International Journal of Cancer|March 10, 2025
Safe prescribing in cancer patients during the COVID-19 pandemic and outcomes following restart of cancer care following SARS-CoV-2 infection: The COV-SPOT initiativeNathan Appanna, Rosie Mew, Sophie Williams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2021
Assessing CSF ctDNA to Improve Diagnostic Accuracy and Therapeutic Monitoring in Breast Cancer Leptomeningeal MetastasisAmanda Fitzpatrick, Marjan Iravani, Adam Mills, et al.
Contemporary Clinical Trials Communications|November 18, 2024
Adapting the design of the ongoing RAMPART trial in response to external evidence: An example for trials which take many years to run and reportAngela Meade, Elena Frangou, Babak Choodari-Oskooei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2026
A Randomized, Phase II Clinical Trial of FLT-PET and FDG-PET for Early Response Assessment of Neoadjuvant Systemic Therapy in Triple Negative Breast CancerMelek Akay, Jennifer Glendenning, Holly Tovey, et al.
Oncoimmunology|October 10, 2015
Elevated IgG4 in patient circulation is associated with the risk of disease progression in melanomaPanagiotis Karagiannis, Federica Villanova, Debra H Josephs, et al.
The Lancet. Oncology|December 24, 2013
Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trialHelena M Earl, Anne-Laure Vallier, Louise Hiller, et al.
Pageof 7